The Joint Q3 Continuing Profit Rises as System Sales Decline

The Joint Corp. reported stronger third-quarter profitability from continuing operations as its transition toward a capital-light franchise model reduced costs, though weaker consumer spending continued to pressure clinic sales. Revenue increased 1% year over year, while system-wide sales declined 3.1% and comparable sales remained negative.

For the quarter ended Sept. 30, 2026, revenue rose to $13.6 million from $13.4 million a year earlier. Net income from continuing operations increased to $1.5 million from $0.3 million, while adjusted EBITDA from continuing operations climbed by $0.9 million to $2.3 million.

The corporate clinic segment is classified as discontinued operations as The Joint completes its refranchising program. Discontinued operations recorded a net loss of $1.6 million, compared with net income of $0.6 million a year earlier, leaving the company with a consolidated net loss of $0.1 million versus net income of $0.9 million in the prior-year period. Consolidated adjusted EBITDA was unchanged at $3.3 million as lower adjusted EBITDA from discontinued operations offset the improvement in continuing operations.

Operating expenses declined across several categories. Cost of revenue fell to $2.4 million from $2.7 million, general and administrative expenses decreased to $6.9 million from $7.3 million, and selling and marketing expenses edged down to $2.7 million from $2.8 million.

Membership Gains Offset by Consumer Pressure

System-wide sales, which include sales from franchised and company-operated or managed clinics, totaled $123.3 million, down 3.1% from the third quarter of 2025. Comparable sales declined 1.9%, although that represented a 90-basis-point improvement from the second quarter of 2026.

The company said improved patient conversion and retention supported sequential growth in active memberships. Patient lifetime value also increased as members remained active for more months and generated higher total spending over their membership period. Those benefits were partly offset by lower average monthly patient spending and fewer new patients, factors management primarily attributed to continued macroeconomic pressure on consumers.

The Joint is seeking to improve comparable sales through AI-supported lead management, greater digital visibility, flexible membership plans and personalized patient engagement. It also plans targeted outreach and promotions to bring back former patients.

New clinics opened in 2026 have reached breakeven in about three months, compared with approximately 18 months historically, according to the presentation. The company intends to attract experienced, well-capitalized multi-unit franchisees, support expansion by existing operators and broaden recruitment through a franchise broker network.

The clinic network totaled 930 locations at quarter-end, including 915 franchised clinics and 15 company-owned or managed locations. As of Nov. 4, 15 lease assignments remained to be completed, after which The Joint expects to have no company-owned or managed clinics.

Guidance Reflects a Smaller Clinic Portfolio

The Joint now expects 2026 system-wide sales of $508 million to $512 million, compared with $532.4 million in 2025. Comparable sales are projected to decline between 2.5% and 3.5%, versus a 0.4% decrease last year. The company maintained its consolidated adjusted EBITDA guidance of $12.5 million to $13.5 million.

The year-end clinic count is expected to be approximately 50 locations below the end of 2025 as the company reshapes its portfolio around what it describes as stronger operators and healthier sites.

Alongside its core chiropractic services, The Joint plans to explore opportunities tied to consumer interest in longevity and healthspan. Its initiatives include testing clinical care protocols with measurable outcomes and piloting complementary retail products such as orthotics and supplements.

Capital Allocation and Risks

The company ended the quarter with $18.3 million of unrestricted cash, down from $22.2 million at June 30, and had full availability under a $20 million revolving credit facility. During the quarter, it repurchased about 461,000 shares for approximately $3.8 million, completing its previous $12 million authorization. The board authorized an additional $5 million for share repurchases after quarter-end.

The Joint also completed five regional developer territory buybacks during 2026. Management expects the reacquired rights to reduce annualized regional developer royalties by about $3 million, with approximately one-third of that benefit offset by the internal costs of managing the territories.

The company identified continued pressure on discretionary consumer spending as a key operating constraint. Other risks include difficulty recruiting chiropractors and other clinic personnel, higher labor costs, inflation, interest rates, tariffs and fuel prices. Execution risks include the completion of remaining lease assignments, the profitable development of the franchise network and the successful integration of reacquired regional developer territories.